相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Peter Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Daniel Wrapp et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu et al.
SCIENCE (2020)
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
Changhai Lei et al.
NATURE COMMUNICATIONS (2020)
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Rui Shi et al.
NATURE (2020)
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells
Yunlong Cao et al.
CELL (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
Emilie Seydoux et al.
IMMUNITY (2020)
High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
Wei Li et al.
CELL (2020)
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Jiangdong Huo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Thomas F. Rogers et al.
SCIENCE (2020)
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Johanna Hansen et al.
SCIENCE (2020)
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Philip J. M. Brouwer et al.
SCIENCE (2020)
SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus
Kuldeep Dhama et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
COVID-19 antibodies on trial
Linda J. Saif et al.
NATURE BIOTECHNOLOGY (2020)
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
Hejun Liu et al.
IMMUNITY (2020)
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
Thomas J. Esparza et al.
SCIENTIFIC REPORTS (2020)
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Michael Schoof et al.
SCIENCE (2020)
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Yufei Xiang et al.
SCIENCE (2020)
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Tania F. Custodio et al.
NATURE COMMUNICATIONS (2020)
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats
Ami Miller et al.
MABS (2020)
Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA
Roberto Melero et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
COMBODY: one-domain antibody multimer with improved avidity
Xuekai Zhu et al.
IMMUNOLOGY AND CELL BIOLOGY (2010)
Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold
Chia-Yu Fan et al.
FASEB JOURNAL (2008)
Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb
Mengyuan Liu et al.
BIOCHEMICAL JOURNAL (2007)
Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants
Jan ter Meulen et al.
PLOS MEDICINE (2006)
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
K Kuba et al.
NATURE MEDICINE (2005)
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells
Y Durocher et al.
NUCLEIC ACIDS RESEARCH (2002)
分享论文
